Phase 1 Evaluation of Elezanumab (Anti–Repulsive Guidance Molecule A Monoclonal Antibody) in Healthy and Multiple Sclerosis Participants

Objective This study was undertaken to describe the safety, tolerability, pharmacokinetics, and immunogenicity of elezanumab (ABT‐555), a fully human monoclonal antibody (mAb) directed against repulsive guidance molecule A (RGMa), in healthy and multiple sclerosis (MS) study participants. Methods Th...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of neurology 2023-02, Vol.93 (2), p.285-296
Hauptverfasser:	Kalluri, Hari V., Rosebraugh, Matthew R., Misko, Thomas P., Ziemann, Adam, Liu, Wei, Cree, Bruce A. C.
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Intravenous Adult Antibodies, Monoclonal - therapeutic use Area Under Curve Central nervous system Cerebrospinal fluid Dosage Dose-Response Relationship, Drug Double-Blind Method Drug therapy Female Healthy Volunteers Humans Immunogenicity Immunomodulation Inflammation Interleukin-10 Interleukins Intravenous administration Male Monoclonal antibodies Multiple sclerosis Multiple Sclerosis - drug therapy Neuroprotection Pharmacokinetics Pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!